- Home
- MTLS vs URGN Comparison
MTLS vs URGN Comparison
Compare MTLS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- URGN
- Stock Information
- Founded
- MTLS 1990
- URGN 2004
- Country
- MTLS Belgium
- URGN United States
- Employees
- MTLS N/A
- URGN N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- URGN Health Care
- Exchange
- MTLS Nasdaq
- URGN Nasdaq
- Market Cap
- MTLS 467.2M
- URGN 547.1M
- IPO Year
- MTLS 2014
- URGN 2017
- Fundamental
- Price
- MTLS $7.45
- URGN $10.64
- Analyst Decision
- MTLS Buy
- URGN Strong Buy
- Analyst Count
- MTLS 1
- URGN 5
- Target Price
- MTLS $9.50
- URGN $44.50
- AVG Volume (30 Days)
- MTLS 220.2K
- URGN 400.5K
- Earning Date
- MTLS 02-19-2025
- URGN 11-06-2024
- Dividend Yield
- MTLS N/A
- URGN N/A
- EPS Growth
- MTLS 323.01
- URGN N/A
- EPS
- MTLS 0.19
- URGN N/A
- Revenue
- MTLS $297,100,156.00
- URGN $89,363,000.00
- Revenue This Year
- MTLS $8.48
- URGN $13.39
- Revenue Next Year
- MTLS $9.65
- URGN $45.06
- P/E Ratio
- MTLS $39.49
- URGN N/A
- Revenue Growth
- MTLS 5.07
- URGN 15.64
- 52 Week Low
- MTLS $4.70
- URGN $10.51
- 52 Week High
- MTLS $8.50
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- MTLS 49.94
- URGN 29.98
- Support Level
- MTLS $7.31
- URGN $11.10
- Resistance Level
- MTLS $8.09
- URGN $11.67
- Average True Range (ATR)
- MTLS 0.42
- URGN 0.55
- MACD
- MTLS -0.11
- URGN -0.15
- Stochastic Oscillator
- MTLS 11.76
- URGN 5.42
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.